Skip to content


  • Poster presentation
  • Open Access

Vascular endothelial growth factor genetic polymorphisms and susceptibility to age-related macular degeneration in Tunisian population

  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1
Journal of Translational Medicine201210 (Suppl 3) :P21

  • Published:


  • Vascular Endothelial Growth Factor
  • Bevacizumab
  • Optical Coherence Tomography
  • Vascular Endothelial Growth Factor Level
  • Serum Vascular Endothelial Growth Factor


Major genetics factors for age-related macular degeneration (AMD) have recently identified as susceptibility risk factors, underlying the role of the vascular endothelial growth factor (VEGF) system in AMD [14].


Our purpose was to determine whether (VEGF) gene polymorphisms play a role in either susceptibility risk for age-related macular degeneration (AMD) serum VEGF levels (s-VEGF) variations and treatment with intravitreal bevacizumab in Tunisians.


The case-control study included 157 patients with AMD and 207 age-matched controls. In all patients, ophthalmological examinations, visual acuity, optical coherence tomography (OCT), fundus photography and fluorescein angiography were performed. Sixty-two patients were treated with intravitreal bevacizumab. Single nucleotide polymorphism (SNP) genotyping (+936 C>T, +405 C>G and -2578 A>G) were performed using direct sequencing. The serum VEGF was assayed by ELISA (R&D).


The single SNP +936 TT and +405 CC genotypes were significantly higher in AMD patients than in controls (p=0.018 and p<10-3, respectively). Haplotype analysis of SNP+936, +405 and -2578 revealed that TGA was associated to exudative form of disease (p<0.0001). However, single allele, genotype and haplotype association analyses showed no significant association with s-VEGF levels variations, clinical forms of AMD or better outcome for distance and reading visual acuity after three bevacizumab injections.


Our results show that VEGF variants do contribute to the susceptibility to AMD in Tunisian patients. Further expression studies are needed to investigate the potential pharmacologic role of these variants in antiangiogenesis therapy.

Authors’ Affiliations

Research Laboratory of Renal Transplantation and Immunopathology (LR03SP01), University Tunis El Manar, Charles Nicolle Hospital, Tunisia
Oculogenetic Research Unit, Dept. B of Ophtalmology, Hedi Rais Institute of Ophthalmology, Tunis, Tunisia


  1. Churchill AJ, Carter JG, Lovell HC: VEGF polymorphisms are associated with neovascular age-related macular degeneration. Human Molecular Genetics. 2006, 15: 2955-61. 10.1093/hmg/ddl238.View ArticlePubMedGoogle Scholar
  2. Fang AM, Lee AY, Kulkarni M: Polymorphisms in the VEGFA and VEGFR-2 gene and neovascular age-related macular degeneration. Molecular Vision. 2009, 15: 2710-19.PubMed CentralPubMedGoogle Scholar
  3. Haines JL, Scbnetz-Boutaud N, Scbmidt S, Scott WK, Agarwal A, Postel EA, Olson L, Kenealy SJ, Hauser M, Gilbert JR, Pericak-Vance MA: Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR and LRP6. IOVS. 2006, 47: 329-335.Google Scholar
  4. Penn JS, Madan A, Caldwell RB: Vascular endothelial growth factor in eye disease. Progress in Retinal and Eye Research. 2008, 27: 331-371. 10.1016/j.preteyeres.2008.05.001.PubMed CentralView ArticlePubMedGoogle Scholar


© Habibi et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.